UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 26, 2004
Anika Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Massachusetts |
|
000-21326 |
|
04-3145961 |
|
(State or Other Jurisdiction of |
|
(Commission File |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
160 New Boston Street, Woburn, Massachusetts |
|
01801 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: (781) 932-6616
Item 5: Other Events and Required FD Disclosure.
On July 26, 2004, Anika Therapeutics, Inc. issued a press release (“Press Release”) announcing the signing of an exclusive worldwide development and commercialization partnership with the Ortho Neutrogena Division of Ortho-McNeil Pharmaceutical, Inc., for its hyaluronic acid based cosmetic tissue augmentation therapy. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.
Item 7: Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release issued by Anika Therapeutics, Inc. on July 26, 2004 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
ANIKA THERAPEUTICS, INC. |
||
|
|
|
|
||
|
July 26, 2004 |
|
By: |
/s/ William J. Knight |
|
|
|
|
|
William J. Knight |
|
|
|
|
|
Chief Financial Officer |
|
3
Exhibit Index
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release of Anika Therapeutics, Inc. dated July 26, 2004 |
4